FILTERED RESULTS
FILTERS
Ads Top
DARK MODE
CHART
    Filters
      Symbols
      Sentiment
      Impact
      Search
      FILTERED RESULTS

        

      Upgrade your plan
      ·

      gild

      ·

      Gilead Acquires Tubulis for $5 Billion

      Gilead Sciences has announced its acquisition of Tubulis, a biotechnology company specializing in antibody-drug conjugates (ADCs), for $5 billion. This move comes sixteen months after the two companies initially partnered to develop ADC therapies.

      The acquisition will enhance Gilead's portfolio in the ADC space, which is a growing area in cancer treatment. Tubulis has been recognized for its innovative approaches in developing targeted therapies that combine antibodies with cytotoxic drugs to improve treatment efficacy while minimizing side effects.

      © 2026 KLEA News. All Rights Reserved. This article is provided for informational purposes only. It is not offered or intended to be used as legal, tax, investment, financial, or other advice.

      Source: KLEA News

      .

      Terra Founder Do Kwon Sentenced to 15 Years in Prison for Fraud